Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 341

Results For "US"

8882 News Found

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
News | September 24, 2025

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion


Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
News | September 24, 2025

Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas

The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines


Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad
News | September 24, 2025

Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad

Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices


Shelter Pharma installs 15 KW solar power plant
Sustainability | September 24, 2025

Shelter Pharma installs 15 KW solar power plant


AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
Drug Approval | September 24, 2025

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population


Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine
Digitisation | September 24, 2025

Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities


Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
Clinical Trials | September 23, 2025

Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer

Importantly, the combination of giredestrant and everolimus was well tolerated